Figure 5.

DMXAA is required for tumor remission after Th/Tc17 CAR T, DMXAA, anti–PD-1, and anti-Gr1 treatment. Animals received injections of anti–PD-1 (200 µg/mouse) and anti-Gr1 (300 µg/mouse) twice weekly, beginning a day after CAR T injection in additional to therapy described in Fig. 2 (Th/Tc17 CAR + D + aP + aG). (A) Schematic describing therapy schedule. (B) Summary of tumor growth (in area) in the first 3 wk after CAR T therapy. (C) Change in tumor area was assessed 7 d after administration of Th/Tc CAR + triple therapy or in the absence of DMXAA, anti–PD-1, anti–Gr-1, or CAR T cells (mock T cells to model the absence of CAR T cells). (D) Kaplan–Meier survival curve indicating mortality over 100 d for the four treatment groups. Data are shown as mean ± SD; ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; significance was determined by Student’s t test or two-way ANOVA when comparing tumor growth change between groups or log-rank Mantel–Cox test when comparing survival. n ≥ 5 mice per group with the data from at least two independent experiments, with the presented data pooled.